Von Eschenbach Resigning In January With BTC Debate In His Legacy
This article was originally published in The Tan Sheet
Executive Summary
FDA Commissioner Andrew von Eschenbach will return to Texas upon resigning his post Jan. 20, leaving a legacy that includes restarting discussions on whether a third class of drugs is needed
You may also be interested in...
Frank Torti’s Next 100 Days: Active, Not Just Acting FDA Commissioner
Frank Torti might not be in charge of FDA for very long, but he seems determined to make his time count
Frank Torti’s Next 100 Days: Active, Not Just Acting, FDA Commissioner
Frank Torti might not be in charge of FDA for very long, but he seems determined to make his time count
Von Eschenbach Slated For Nomination As Permanent FDA Head
FDA Acting Commissioner and National Cancer Institute Director Andrew von Eschenbach, MD, will likely be nominated by President George W. Bush as permanent agency head, former FDA Associate Commissioner for External Relations Peter Pitts said March 9